COGA Trial Validates Superiority of Truscreen

GENERAL
Tue, Apr 05 2022 08:30 am

NZX/ASX Announcement

5 April 2022

COGA TRIAL VALIDATES SUPERIORITY OF TRUSCREEN
CERVICAL CANCER SCREENING METHOD

• COGA Trial screened 15,661 women across 64 hospitals in 9 provinces over 3 years
• TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
• TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
• TruScreen was determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to announce the release of a China-based cervical cancer screening trial which validated the superiority of TruScreen’s screening method.

The Chinese Obstetricians and Gynaecologists Association (COGA) completed a much anticipated, detailed cervical cancer screening trial that commenced in September 2018 and concluded in July 2021. The results of this trial have just been released and presented at a research conference organised by ASCCP (American Society of Colposcopy and Cervical Pathology) held in San Diego, USA. It compared the relative effectiveness of TruScreen against two other cervical cancer screening methods of HPV DNA testing (HPV) and Liquid Based Cytology (LBC).

Chinese trial highlights superiority of TruScreen screening method
The released results of the COGA trial, like those for earlier TruScreen studies, determined TruScreen to be a simple, effective and rapid real-time method to screen for cervical cancer. The COGA trial results also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing.

The size of the COGA study, which was TruScreen’s largest clinical evaluation to date, lends extra significance to its results and broad conclusions. It involved the screening in a clinical setting of 15,661 women aged 21 years and older across 64 teaching hospitals in 9 Chinese provinces. All the women included in the trial underwent primary screening with TruScreen, HPV and LBC, where levels of sensitivity and specificity were computed. The results of the study found:
• TruScreen's sensitivity was well above that for LBC (87.5% v’s 66.5%), with a high degree of statistical significance (p<0.001).
• TruScreen’s specificity (88.4%) was higher than both LBC (86.3%) and hrHPV testing (78.3%) (also at p<0.001).
• The sensitivity of TruScreen-hrHPV co-testing (carrying out with multiple types of screening tests at the same time, as opposed to a single type) was higher than that of LBC-hrHPV co-testing, 98.4% vs 95.9% (statistically significant at p=0.006).
COGA concluded that the study highlighted the superiority of TruScreen’s screening method, with the Association noting that:
• Due to resource restrictions, cytology cannot be effective in mass population screening programs in the areas with high morbidity and mortality of cervical cancer
• TruScreen minimizes the need for training and facilities and offers a real-time result
• Given the above two points, TruScreen is appropriate as a primary screening tool in regions with high morbidity and mortality to cervical cancer.

Juliet Hull, TruScreen’s Chief Executive Officer said: “Our thanks to Beijing Siweixiangtai Tech Co Ltd (SWXT), our Chinese distributor for their dedication and management of the 3-year clinical trial of our TruScreen cervical cancer screening technology. SWXT and TruScreen have achieved a significant milestone in the commercialisation of our technology in China. The validation of our technology by COGA together with the recent national price approval of our TruScreen device (NZX announcement 3 March 2022) have provided opportunities for SWXT to further expand distribution of our TruScreen cervical cancer screening technology in China. Importantly, the study’s results also point to the potential benefits of TruScreen-HPV co-testing. This is another opportunity for growth as the Company continues its successful expansion into China and other overseas markets.”

This announcement was approved for release by the Board.

-ENDS-

For more information, visit www.truscreen.com or contact:

Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Announcement PDF

Markets News

Markets
How to survive a bear market
Dan Brunskill | Fri, 24 Jun 2022

Bear markets can be stressful but they also present opportunities for investors, says Salt Funds' Greg Fleming.  

Markets FREE
Index heavyweights pull NZ shares higher
Ella Somers | Thu, 23 Jun 2022

Peter McIntyre, an investment adviser at Craigs Investment Partners, said it had been a “strong performance” in today’s market.

Infrastructure
How we can fix New Zealand's ports – Don Braid
Brent Melville | Thu, 23 Jun 2022

The head of the multinational logistics group says having container cranes sitting idle across the country is a waste of assets

Markets Exclusive
Investment platform Stake brings stock lending to NZ
Dan Brunskill | Thu, 23 Jun 2022

The zero-brokerage fee share trading platform is looking for ways to bring in revenue and make its business model more sustainable. 

Infrastructure
Fletcher to deliver at least $850m operating earnings in 2023
Jenny Ruth | Thu, 23 Jun 2022

Fletcher Building achieved second-half profit margins of 9.5%, just below its target of 10% by the 2023 financial year.

Markets market close
NZ shares fall as Eroad near all-time low
Dan Brunskill | Wed, 22 Jun 2022

Eroad had a second day as the index’s biggest decliner, falling more than 5% to $1.57 and bringing its decline over the past year to almost 75%.

Infrastructure
Fletcher said Gib orders reached double capacity
Staff reporters | Wed, 22 Jun 2022

Fletcher's new plant at Tauriko, due to open next year, will increase industry capacity by 30%.

Infrastructure
Craigs recommends investors be ‘overweight’ Fletcher shares
Jenny Ruth | Wed, 22 Jun 2022

Even under a “bear-case scenario”, the house building pipeline should support Fletcher’s medium-to-long-term performance.

Markets FREE
NZ shares rise as recession fears ease
Ella Somers | Tue, 21 Jun 2022

Some investors in NZ’s market took the opportunity to buy up “beaten up” stock on the index today, Devon Funds' Greg Smith said.

Markets market close
NZ shares flat as recession risk puts investors off trading
Dan Brunskill | Mon, 20 Jun 2022

Trading volumes were unusually light, with US markets closed tonight for a national holiday.

Infrastructure
NZSA, Simplicity call for Fletcher chair Bruce Hassall to resign
Jenny Ruth | Mon, 20 Jun 2022

The shareholder representatives say the Fletcher board must bear ultimate responsibility for the company’s poor performance and the Gib plasterboard shortage.

Markets
NZME makes up for slow buyback with $10m special dividend
Dan Brunskill | Mon, 20 Jun 2022

NZME has only spent $5.3m of the $30m set aside for share buybacks. 

Markets
Macquarie says Australian banks are profiting from low term deposit rates
Dan Brunskill | Mon, 20 Jun 2022

Are banks being too slow to raise term deposit rates? Some analysts say yes. 

Markets Market Close
Cautious trading follows week of share market turmoil
Ella Somers | Fri, 17 Jun 2022

Peter McIntyre, an investment adviser at Craigs Investment Partners, says New Zealand’s market has been "reliably well-behaved over the course of the day".

Technology
Fabrum open to listing to keep up with hydrogen demand
Brent Melville | Fri, 17 Jun 2022

The firm has doubled its headcount and is looking to raise capital to expand its manufacturing and engineering focus into green hydrogen applications.

Energy
Australia's electricity train wreck has lessons for NZ
Ian Llewellyn | Fri, 17 Jun 2022

Meridian says the fact that Australia's electricity market has turned into a train wreck shows its decision to pull out was the right one.

Primary Sector
Government favours Fonterra’s commercial interests: MPI
Jenny Ruth | Fri, 17 Jun 2022

The Ministry for Primary Industries estimated Fonterra’s restructuring would cost the average farmer between $135,000 and $400,000.

Transport
HW Richardson takes 'uncommercial' plunge into hydrogen
Brent Melville | Fri, 17 Jun 2022

New Zealand's biggest transport operator plans to have its first 10 dual-fuel hydrogen trucks on the road next year. 

Markets market close
NZ share market climbs as US Federal Reserve hikes interest rates
Dan Brunskill | Thu, 16 Jun 2022

Oanda market analyst Edward Moya said the absence of a Bitcoin rally could be a troubling sign for some investors.

Media ANALYSIS
Wounded Sky under pressure to return cash after MediaWorks U-turn
Daniel Dunkley | Thu, 16 Jun 2022

Sky TV and MediaWorks will be brushing themselves off after a bruising response to their proposal scotched a SkyWorks deal.

Media
Sky pulls out of MediaWorks takeover
Daniel Dunkley | Thu, 16 Jun 2022

Sky TV has backed away from a dalliance with radio and outdoor advertising.

Markets
Mere mortals: investor confidence ebbs
Dan Brunskill | Thu, 16 Jun 2022

An annual survey of investor confidence shows the market fall has got some people rattled. 

Primary Sector
Fonterra restructure 'not in the national interest', says report
Jenny Ruth | Thu, 16 Jun 2022

It's important that constraints remain on Fonterra that counterbalance its privileged position in the dairy sector and the national economy, says TDB Advisory.

Markets market close
NZ shares stabilise as US Fed meets
Dan Brunskill | Wed, 15 Jun 2022

BNZ Research said there was now “a good chance” the Reserve Bank of NZ would hike 75 basis points when it meets next month.